The historical rank and industry rank for Dynavax Technologies's FCF Margin % or its related term are showing as below:
DVAX'
s FCF Margin % Range Over the Past 10 Years
Min: -23910.4 Med: -324.86 Max: 74.2
Current: 21.7
During the past 13 years, the highest FCF Margin % of Dynavax Technologies was 74.20%. The lowest was -23910.40%. And the median was -324.86%.
DVAX's FCF Margin % is ranked better than 91.63% of 980
companies
in the Drug Manufacturers industry
Industry Median: 0.87
vs DVAX: 21.70
Dynavax Technologies FCF Margin % Historical Data
The historical data trend for Dynavax Technologies's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Dynavax Technologies's FCF Margin %
For the Drug Manufacturers - Specialty & Generic subindustry, Dynavax Technologies's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Dynavax Technologies's FCF Margin % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Dynavax Technologies's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Dynavax Technologies's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Dynavax Technologies FCF Margin % Related Terms
Thank you for viewing the detailed overview of Dynavax Technologies's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DVAX has been successfully added to your 